Quidel

News Release

Printer Friendly Version View printer-friendly version
<< Back
Quidel Appoints Ernst & Young as Independent Public Accountants
SAN DIEGO, Apr 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quidel Corporation (Nasdaq: QDEL), a worldwide leader in developing, manufacturing and marketing point-of-care (POC) rapid diagnostic tests for the detection and management of a variety of medical conditions and illnesses, today announced that its Board of Directors has appointed Ernst & Young LLP, as Quidel's independent public accountants. The appointment of Ernst & Young LLP was made after careful consideration by Quidel's Board of Directors and upon the recommendation of the Company's Audit Committee.

Prior to the selection of Ernst & Young LLP, Arthur Andersen LLP had served as Quidel's independent public accountants. Quidel's decision to change independent public accountants, for the fiscal year ending December 31, 2002, was not the result of any disagreement between Quidel and Arthur Andersen LLP on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedure.

The Company stated that Arthur Andersen LLP has provided excellent service to Quidel and Quidel has valued its relationship with the firm.

About Quidel

Quidel Corporation discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health, in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs and increase patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com .

CONTACT:
Martin Halsall, mhalsall@lhai.com, or Bruce Voss,
bvoss@lhai.com, both of Lippert/Heilshorn & Associates, +1-310-691-7100, for
Quidel Corporation; or Paul E. Landers, Vice President & CFO of Quidel
Corporation, +1-858-552-7962